Key Takeaways
- • UK biotech venture capital reached £270 million in Q3 2026, up 44% from £187 million in the same quarter last year, according to the BioIndustry Association (BIA), putting the sector on track for its best year since 2021.
- • Year-to-date UK biotech venture investment totals £2.8 billion, already exceeding any full year from 2022 to 2025; the 2021 record stands at £3 billion.
- • Basecamp Research led the quarter with a £104 million Series C to train AI models and advance AI-designed medicines toward the clinic.
- • UK biotech follow-on financing reached only £151 million in Q3, with Silence Therapeutics' £130 million NASDAQ raise accounting for most of it, and no UK biotech IPOs have occurred for 17 quarters.
- • BIA chief executive Chris Molloy called on British investors and government to recycle returns into the domestic ecosystem.
Summary
British biotech venture capital investment reached £270 million in the third quarter of 2026, up 44% from £187 million in the same period last year, according to new figures from the BioIndustry Association (BIA). The growth positions the sector for its best year since 2021, though the quarter-on-quarter comparison is weaker: Q2 totaled £2.1 billion, driven by Isomorphic Labs' £1.6 billion Series B. The BIA said the quarterly decline is consistent with broader UK venture trends.
Year-to-date venture investment stands at £2.8 billion, already more than any full year from 2022 to 2025. The record year remains 2021, when £3 billion was raised. Isomorphic Labs' £1.6 billion raise and CellCentric's £163 million raise, both in the second quarter, have driven much of the 2026 total.
Basecamp Research led Q3 deal flow with a £104 million Series C, which it will use to train next-generation AI models and push AI-designed medicines toward the clinic. The BIA noted that NVIDIA, which counts Basecamp among the UK start-ups it backs, announced new planned investments in two more London AI biology companies this month, a signal the BIA cited as evidence that life sciences and AI are converging in the UK with backing from big pharma and big tech.
Total UK biotech equity raised in Q3 reached £421 million, up 113% from £198 million a year earlier. The UK captured 26% of the European total venture figure of £1.1 billion, retaining its position as the top destination for venture capital in the region.
Significant gaps remain. Follow-on financing reached only £151 million, most of it from Silence Therapeutics' £130 million NASDAQ raise, and the UK biotech IPO window has been shut for 17 consecutive quarters.
BIA chief executive Chris Molloy said UK science attracts expert global capital, but returns are not being recycled domestically because too few British investors participate in either private or public markets. He said government has a role in improving the environment and incentivising wealth creators to reinvest their gains.
Year-to-date venture investment stands at £2.8 billion, already more than any full year from 2022 to 2025. The record year remains 2021, when £3 billion was raised. Isomorphic Labs' £1.6 billion raise and CellCentric's £163 million raise, both in the second quarter, have driven much of the 2026 total.
Basecamp Research led Q3 deal flow with a £104 million Series C, which it will use to train next-generation AI models and push AI-designed medicines toward the clinic. The BIA noted that NVIDIA, which counts Basecamp among the UK start-ups it backs, announced new planned investments in two more London AI biology companies this month, a signal the BIA cited as evidence that life sciences and AI are converging in the UK with backing from big pharma and big tech.
Total UK biotech equity raised in Q3 reached £421 million, up 113% from £198 million a year earlier. The UK captured 26% of the European total venture figure of £1.1 billion, retaining its position as the top destination for venture capital in the region.
Significant gaps remain. Follow-on financing reached only £151 million, most of it from Silence Therapeutics' £130 million NASDAQ raise, and the UK biotech IPO window has been shut for 17 consecutive quarters.
BIA chief executive Chris Molloy said UK science attracts expert global capital, but returns are not being recycled domestically because too few British investors participate in either private or public markets. He said government has a role in improving the environment and incentivising wealth creators to reinvest their gains.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.